VEGFA and hepatocellular carcinoma: The IMbrave150 trial (2020) was a phase III clinical trial that evaluated atezolizumab (PD-L1 inhibitor) in combination with bevacizumab (vascular endothelial growth factor- [VEGF] inhibitor) compared to sorafenib in unresectable HCC.3